Health economic evaluations help inform payers of the best use of scarce health care resources

International Journal of Circumpolar Health

Volumn 70, Issue 4, 2011, Pages 419-427

  O'Reilly, Daria ^a,b   Gaebel, Kathryn ^a,b   Xie, Feng ^a,b   Tarride, Jean Eric ^a,b   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Cost utility analysis; Costing; Economic evaluation; Resource allocation

Indexed keywords

ARTICLE; CANADA; COLD CLIMATE; COST; DECISION MAKING; ECONOMICS; HEALTH CARE PLANNING; HEALTH SERVICES RESEARCH; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; RURAL POPULATION;

CANADA; COLD CLIMATE; COSTS AND COST ANALYSIS; DECISION MAKING; HEALTH RESOURCES; HEALTH SERVICES RESEARCH; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RURAL POPULATION;

EID: 80053216454     PISSN: 12399744     EISSN: None     Source Type: Journal    
DOI: 10.3402/ijch.v70i4.17843     Document Type: Article

References (18)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford (UK): Oxford University Press; 2005. 379 p.
2. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12(4):361-370.
3. Blackhouse G, Xie F, Campbell K, Assasi N, Gaebel K, Levine M, et al. Intravenous immunoglobulin for treatment of idiopathic thrombocytopenic purpura: economic and health service impact analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. 57 p.
4. Carson JB, Postl BD, Spady D, Schaefer O. Lower respiratory tract infections among Canadian Inuit children. In: Fortuine R, editor. Circumpolar health 84. Proceedings of the Sixth International Symposium on Circumpolar Health. Seattle: University of Washington Press; 1984. p. 226-228.
5. Canadian Paediatric Society. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4(7):474-489.
6. Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354(9181):847-852.
7. Banerji A. High rates of hospitalisation for bronchiolitis in Inuit children on Baffin Island. Int J Circumpolar Health 2001;60(3):375-379.
8. Banerji A, Bell A, Mills EL, McDonald J, Subbarao K, Stark G, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164(13):1847-1850.
9. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health 2007;12(7):563-566.
10. Langley JM, Wang EE, Law BJ, Stephens D, Boucher FD, Dobson S, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131(1 Pt 1):113-117.
11. Banerji A, Lanctot KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28(8):702-706.
12. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-537.
13. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-540.
14. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-S156.
15. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346(13):995-1008.
16. Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005;94(2):178-184.
17. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007;21(2 Suppl 1):S9-S56.
18. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88(1):3-40.